The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their exclusivity periods.

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa. Efimosfermin is an investigational long-acting variant of FGF21 protein designed to treat and prevent the progression of steatotic liver disease (SLD),

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.